RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
about
Tumor metastasis to boneRANK-RANKL signalling in cancerBone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaThe Modulatory Effects of Mesenchymal Stem Cells on OsteoclastogenesisCan heparins stimulate bone cancer stem cells and interfere with tumorigenesis?Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidencesManagement of Ewing sarcoma family of tumors: Current scenario and unmet needTGF-β Signaling in Bone Remodeling and Osteosarcoma ProgressionPotassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal diseaseTargeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasisUsing GWAS to identify novel therapeutic targets for osteoporosis.Genetic polymorphism of the OPG gene associated with breast cancer.Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer.Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression.Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in CaucasiansSelective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastasesTherapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasisIncreased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta.Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells.Renal cell carcinoma bone metastases: clinical advancesMathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma.Development of a brain metastatic canine prostate cancer cell line.Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran.The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas.Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.Effects of a sulfated exopolysaccharide produced by Altermonas infernus on bone biology.Denosumab: a new option in the treatment of bone metastases from urological cancersOsteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKLThe Function of Naringin in Inducing Secretion of Osteoprotegerin and Inhibiting Formation of Osteoclasts.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Design of a RANK-Mimetic Peptide Inhibitor of Osteoclastogenesis with Enhanced RANKL-Binding AffinityZoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patientsBone metabolism compensates for the delayed growth in small for gestational age neonates.
P2860
Q21195416-61CEF388-2FF1-46B5-A373-374F2DF60E52Q26747442-E5224ACC-2301-4352-A2F4-B51FFD23E9E5Q26771376-989575D5-6C21-4B0E-BF38-DC87698B2D85Q26773017-0F2505E5-4B61-4D97-832E-17AF0EF96636Q26852760-8420974E-3E7C-4BDF-B1A6-FB0BA81BDAE6Q26863493-5E7D89D9-0E2E-4E60-A988-A6B3DAF69D77Q28073218-5F47960D-3872-446D-8F8E-B9E52E81D874Q28076815-0528A109-3D88-44DA-B915-14C2C61967A0Q28252713-D91533C8-01F2-492D-923D-5C669B22DFE4Q28731449-C372373A-1D4A-4C6A-9101-D9BCC534A8F0Q30275429-8A66C02E-ABAF-4A66-8637-7A2A276AFF41Q30534404-5410BBBA-FBCA-425C-BBFB-081ED66FF52AQ30573685-9399656D-9B33-44D5-B4B0-01489B9E1294Q30596578-B795495F-15C0-4E5B-B178-5E1BD2431545Q33293423-1DBDD682-635B-46B9-A35B-292BB84E36B1Q33358300-94841840-D456-40BA-B9D7-3B65ABBD18DEQ33920086-74DE7C01-C11B-4138-A2B9-EBBBA752C211Q34044214-CA5ED2EB-279D-4DA2-9FD4-6A33918CACF9Q34090842-C4DA9A7B-AE6A-4ADB-A81F-C93EAF3ACC91Q34101059-732083D1-576E-4F4D-8217-875C616F9658Q34147824-9186CF1F-2FEB-4C63-8BE2-3A1E91A33097Q34148428-9B747ED0-E8FB-435A-9EE6-1116B396FC07Q34207923-C87AEC82-4483-4091-9C0C-3CCD3EBAEB6BQ34356336-4DADE076-EEED-4B51-9AA7-6CDF6EDD7607Q34631216-A5322238-F965-49F2-B0C8-1D5EE5BD5517Q34806153-70420DD8-B75D-4E82-B425-0FFBBDB2A768Q35115283-9BBE90CF-2B01-44E0-B35A-6269FFB3B146Q35116018-E8F8035E-4993-47C9-A51B-4CBAC9DBF856Q35133898-3979D8B5-6931-4773-87DA-007D8F9C9AB6Q35214241-570CBE21-EF00-4EA2-A181-F2D600FE8BFBQ35611366-8FA76679-B206-439E-AB4C-730AC05B0FA3Q35688200-54F1BAF5-51E3-469B-9AEC-73F2602DADF4Q36103172-90AC9163-D53E-45B5-847B-9FDC35B9406DQ36277837-CB036CE1-CD63-40C3-832C-532C0A477E73Q36491545-64740F81-8B75-42FA-85DB-012306E00E09Q36537771-0AF527E7-A425-4FA2-9B20-9A2658D0D77CQ36759374-ED1EF7D2-EA21-48D9-BC0A-CF9774DDD931Q36835372-64DD89F8-02C0-49CE-805B-17DF48E3DF4BQ36846801-23C99F99-F6D5-4D8E-9C9E-636ABFEA6094Q36906149-6C2FDBF4-9E33-47C8-BA48-1D19FC363ABE
P2860
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
@ast
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
@en
type
label
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
@ast
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
@en
prefLabel
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
@ast
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
@en
P2093
P1476
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
@en
P2093
P356
10.1016/J.BBCAN.2004.05.002
P407
P577
2004-09-01T00:00:00Z